All In Biotech

Drug Trial Radar · NCT05902988

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

A Phase I/II Study of VLS-1488 (an Oral KIF18A Inhibitor) in Subjects With Advanced Cancer

Last checked: Nov 19, 2026Latest source record: Nov 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Oct 18, 2023

Primary completion

Jun 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Volastra Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jun 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.

Conditions

  • Advanced Solid Tumor
  • High Grade Serous Adenocarcinoma of Ovary
  • Squamous Non-small-cell Lung Cancer
  • Triple Negative Breast Cancer
  • Head and Neck Squamous Cell Carcinoma
  • Ovarian Carcinosarcoma
  • Uterine Carcinosarcoma
  • Uterine Serous Carcinoma
  • Endometrium Cancer
  • Chromosomal Instability

Interventions

  • VLS-1488Drug

    VLS-1488 tablets will be given orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Escalation: Incidence of Dose Limiting Toxicities (DLTs) in DLT-evaluable subjectsTime frame: Up to 12 months
  2. Dose Escalation: Determination of the MTD of VLS-1488Time frame: Up to 12 months
  3. Dose Escalation: Frequency of Serious Adverse Events (SAEs) graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0Time frame: Up to 12 months
  4. Dose Escalation: Frequency of Treatment-related Adverse Events (AEs) graded per NCI-CTCAE version 5.0Time frame: Up to 12 months
  5. Dose Escalation: Frequency of Treatment-Emergent AEs (TEAEs) graded per NCI-CTCAE version 5.0Time frame: Up to 12 months
  6. Dose Escalation: Frequency of Dose Interruptions and Permanent Treatment DiscontinuationsTime frame: Up to 12 months
  7. Dose Expansion: Frequency of Trigger Events (TEs)Time frame: Up to 18 months
  8. Dose Expansion: Objective Response Rate (ORR) as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1Time frame: Up to 18 months

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • University of Southern California

    Los Angeles, California · Recruiting

  • Hoag Memorial Hospital

    Newport Beach, California · Recruiting

  • University of Colorado Cancer Center

    Aurora, Colorado · Recruiting

  • Yale Cancer Center

    New Haven, Connecticut · Recruiting

  • Kellogg Cancer Center

    Evanston, Illinois · Recruiting

  • Community Health Network

    Indianapolis, Indiana · Recruiting

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

    Baltimore, Maryland · Recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • START Midwest

    Grand Rapids, Michigan · Active not recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • The Christ Hospital

    Cincinnati, Ohio · Recruiting

  • Women & Infants Hospital

    Providence, Rhode Island · Recruiting

  • M.D. Anderson Cancer Center

    Houston, Texas · Recruiting

  • Froedtert & the Medical College of Wisconsin

    Milwaukee, Wisconsin · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.